Remifentanil Versus Rocuronium for Optimizing Video Laryngoscopy-assisted Tracheal Intubation in Patients Undergoing General Anaesthesia - a Multicentre Randomised Controlled Trial -The ROCVIDEO Trial

Globally, we are approaching 1 million surgical procedures each day. Tracheal intubation is the mainstay of securing the patient's airway and breathing during general anaesthesia. Approximately 100.000 tracheal intubations are performed annually in Denmark. Airway management remains the primary reason for anaesthesia-related morbidity and mortality. It has been traditionally accepted that best tracheal intubation conditions are obtained by paralysing the patient's muscles, including vocal cords, using a neuromuscular blocking agent (NMBA) such as rocuronium. However, using NBMA may increase the risk of pulmonary complications, intra-operative awareness, in which the patient is paralysed but awake during surgery, anaphylaxis, and re-intubation. In addition, there is a risk of residual neuromuscular blockade postoperatively. In the US, prolonged ventilation and unplanned intubation are the top two most costly perioperative complications. An alternative to NMBA is a large dose of opioids to depress laryngeal reflexes during intubation. The most commonly used non-NMBA modality includes bolus administration of remifentanil. However, remifentanil may cause bradycardia and hypotension. Even short periods of hypotension have been shown to increase the risk of myocardial injury and other serious adverse events such as renal failure, delirium, and even mortality.
Evidence also indicates that intubation conditions using only opioids to facilitate intubation, including remifentanil, are inferior to NMBA. However, these trials are underpowered to assess effects on patient-important outcomes and are mostly at high risk of bias. A recent trial has suggested that remifentanil intubation conditions may not be very different. Almost all existing research comparing NMBA to opioids has focused on intubation conditions for direct laryngoscopy using a conventional Macintosh laryngoscopy blade. In recent years, the implementation and availability of the video laryngoscope have grown exponentially and become universal. The video laryngoscope has vastly improved the ease of tracheal intubation, and the number of failed intubations has decreased by two-thirds in Denmark, where a rapid implementation of the video laryngoscope took place. However, limited evidence exists on whether NMBA improves intubation conditions compared to remifentanil when performing video laryngoscope-assisted tracheal intubation.

Start Date01 Jun 2025

Sponsor / Collaborator-

ChiCTR2400092060 / SuspendedNot ApplicableIIT

Effect of low-dose remifentanil pumped after operation on restlessness and hemodynamics in patients with hypertension during Allen Su during thoracoscopic lobectomy

Start Date01 Dec 2024

Sponsor / Collaborator

Anhui Medical University No. 1 Affiliated Hospital

ChiCTR2400091614 / SuspendedNot ApplicableIIT

The evaluation of the application of anesthesia depth monitoring based on EEG wavelet algorithm in target-controlled infusion anesthesia with propofol and remifentanil

Start Date01 Nov 2024

Sponsor / Collaborator-

100 Clinical Results associated with Remifentanil Hydrochloride

100 Translational Medicine associated with Remifentanil Hydrochloride

100 Patents (Medical) associated with Remifentanil Hydrochloride

6,336

Literatures (Medical) associated with Remifentanil Hydrochloride

01 Jan 2025·Brain, Behavior, and Immunity

Remifentanil-induced inflammation in microglial cells: Activation of the PAK4-mediated NF-κB/NLRP3 pathway and onset of hyperalgesia

Article

Author: Cui, Chang ; Dong, Shuhua ; Chen, Benzhen ; Zhang, Tianyao ; Wu, Xiaochu

BACKGROUNDThe perioperative use of remifentanil is associated with postoperative hyperalgesia, which can impair recovery and extend hospitalization. Recent studies have revealed that microglia-mediated activation of the NLRP3 inflammasome plays a critical role in opioid-induced hyperalgesia, with NF-κB acting as a pivotal activation point for NLRP3. Despite these findings, the specific molecular mechanisms underlying remifentanil-induced postoperative hyperalgesia remain unclear. This study aims to develop a model of remifentanil-induced hyperalgesia and investigate the molecular mechanisms, focusing on the NF-κB/NLRP3 pathway, using both in vitro and in vivo approaches.METHODWe established a remifentanil-induced hyperalgesia model and performed proteomic analysis to identify differential protein expression in the spinal cord tissue of rats. NLRP3 or PAK4 antagonists were administered intrathecally in vivo, and mechanical pain thresholds in the hind paws were measured using Von Frey testing. In vitro, we applied NLRP3 or PAK4 inhibitors or used lentivirus infection to silence PAK4, NF-κB, and NLRP3 genes. Protein expression was assessed through immunohistochemistry, immunofluorescence, and Western blotting. Additionally, ELISA was performed to measure IL-1β and IL-18 levels, and RT-qPCR was conducted to evaluate the transcription of target genes.RESULTSProteomic analysis revealed that remifentanil upregulates PAK4 protein in spinal cord tissue two hours after the surgery. In addition, remifentanil induces morphological changes in the spinal cord dorsal horn, characterized by increased expression of PAK4, p-p65, NLRP3 and Iba-1 proteins, which in turn leads to elevated IL-1β and IL-18 levels and an inflammatory response. Intrathecal injection of NLRP3 or PAK4 inhibitors mitigates remifentanil-induced hyperalgesia and associated changes. In vitro, downregulation of PAK4 inhibits the increase in PAK4, p-p65, NLRP3 and Caspase-1 induced by LPS. Conversely, the downregulation of NLRP3 does not impact the levels of PAK4 and p-p65 proteins, aligning with the in vivo results and suggesting that PAK4 acts as an upstream signaling molecule of NLRP3.CONCLUSIONRemifentanil can increase PAK4 expression in spinal cord dorsal horn cells by activating the NF-κB/NLRP3 pathway and mediating microglial activation, thereby contributing to postoperative hyperalgesia.

01 Jan 2025·Brazilian Journal of Anesthesiology (English Edition)

Comparison of the recovery profile of sufentanil and remifentanil in total intravenous anesthesia: a systematic review and meta-analysis of randomized controlled trials

Review

Author: Cuiabano, Igor Seror ; Naves, Rafael Pagliaro ; Diehl, Rodrigo Bouchabki de A. ; Diehl, Rodrigo Bouchabki de A

INTRODUCTIONRemifentanil is a short-acting opioid and can be administered during surgery without the risk of delayed postoperative recovery but concerns about hyperalgesia and the shortages of remifentanil lead anesthetists to consider long-acting opioids for Total Intravenous Anesthesia (TIVA). Sufentanil is a more potent opioid with a longer context-sensitive half-life but can promote good postoperative analgesia due to its residual effect. This meta-analysis aimed to compare the recovery profile of remifentanil and sufentanil for TIVA.METHODSThe search strategy was performed in PubMed, CENTRAL, and Web of Science for RCTs comparing sufentanil and remifentanil as part of TIVA in adults undergoing noncardiac surgery. Risk of bias and the quality of evidence were performed using RoB2 and GRADEpro, respectively. The primary outcome was time to tracheal extubation. Secondary analyses included postoperative analgesia, respiratory depression, and Postoperative Nausea and Vomiting (PONV).RESULTSSufentanil increases the time to extubate, MD = 4.29 min; 95% CI: 2.33 to 6.26; p = 0.001. It also reduces the need for postoperative rescue analgesia, logOR = -1.07; 95% CI: -1.62 to -0.52; p = 0.005. There were no significant differences between both opioids for PONV, logOR = 0.50; 95% CI: -0.10 to 1.10; p = 0.10 and respiratory depression, logOR = 1.21; 95% CI: -0.42 to 2.84; p = 0.15.CONCLUSIONSufentanil delays the time to tracheal extubation compared with remifentanil but is associated with a reduced need for postoperative rescue analgesia. No significant differences were observed between the two opioids in terms of postoperative respiratory depression or PONV.

31 Dec 2024·Annals of Medicine

Efficacy of intraoperative systemic lidocaine on quality of recovery after laparoscopic colorectal surgery: a randomized controlled trial

Article

Author: Zhuo, Yifen ; Guo, Yanhua ; Qiu, Chunlin ; Yao, Yusheng ; Yang, Ying ; Lin, Wenjun

INTRODUCTIONMany clinical trials have demonstrated the benefits of intraoperative systemic lidocaine administration in major abdominal surgeries. We tested the hypothesis that systemic lidocaine is associated with an enhanced early quality of recovery in patients following laparoscopic colorectal resection.PATIENTS AND METHODSWe randomly allocated 126 patients scheduled for laparoscopic colorectal surgery in a 1:1 ratio to receive either lidocaine (1.5 mg kg^-1 bolus over 10 min, followed by continuous infusion at 2 mg kg^-1 h^-1 until the end of surgery) or identical volumes and rates of saline. The primary outcome was the Quality of Recovery-15 score assessed 24 h after surgery. Secondary outcomes were areas under the pain numeric rating scale curve over time, 48-h morphine consumption, and adverse events.RESULTSCompared with saline, systemic lidocaine improved the Quality of Recovery-15 score 24 h postoperatively, with a median difference of 4 (95% confidence interval: 1-6; p = 0.015). Similarly, the area under the pain numeric rating scale curve over 48 h at rest and on movement was reduced in the lidocaine group (p = 0.004 and p < 0.001, respectively). However, these differences were not clinically meaningful. Lidocaine infusion reduced the intraoperative remifentanil requirements but not postoperative 48-h morphine consumption (p < 0.001 and p = 0.34, respectively). Additionally, patients receiving lidocaine had a quicker and earlier return of bowel function, as indicated by a shorter time to first flatus (log-rank p < 0.001), yet ambulation time was similar between groups (log-rank test, p = 0.11).CONCLUSIONSIn patients undergoing laparoscopic colorectal surgery, intraoperative systemic lidocaine resulted in statistically but not clinically significant improvements in quality of recovery (see Graphical Abstract).Trial registration: Chinese Clinical Trial Registry; ChiCTR1900027635.

News (Medical) associated with Remifentanil Hydrochloride

08 Aug 2024

·www.echemi.com

Humanwell Healthcare Reports 3.86% Revenue Growth in H1 2024

The latest release shows that Humanwell Healthcare has delivered remarkable results in the first half of 2024, demonstrating excellent market performance. Specifically, the company managed to achieve solid growth in total operating revenue, totaling RMB12.861 billion, an increase of 3.86% over the same period last year, marking the fourth consecutive year of good growth for Humanwell Healthcare. Despite some fluctuations in net profit, Humanwell Healthcare's core subsidiary, Yichang Humanwell, maintained strong growth momentum and achieved double-digit growth rates, providing strong support for the company's overall performance. As a leading pharmaceutical company in China, Humanwell Healthcare has been committed to the research and development, production and sales of pharmaceutical products since its establishment in 1993. Headquartered in Wuhan, Hubei Province, Humanwell Healthcare is a key player in China's pharmaceutical industry. Humanwell Healthcare's product line is rich and diverse, including many star products. Compound Cloloterol propionate tablet, as one of the company's core products, is an oral drug for type 2 diabetes, which has the effect of significantly reducing blood sugar and protecting islet function, and enjoys a high reputation in the field of diabetes treatment in China. Gastrodine capsule is a Chinese medicine preparation for the treatment of ischemic stroke sequelae, which can significantly improve the blood supply to the brain and promote the repair of nerve function, and is an important representative of the company in the field of Chinese medicine. In addition, as the company's main product in the field of respiratory treatment, trimebutin tablets can effectively improve the respiratory function of patients with chronic obstructive pulmonary disease (COPD), and occupy an important position in the domestic COPD treatment market. Humanwell Healthcare continues to consolidate and expand its market leadership in the key area of neurological medicine. The company's two star narcotic products - remifentanil hydrochloride for injection and sufentanil citrate injection, the performance of the national hospital market in 2023 is particularly eye-catching. The combined sales of these two products reached 6.778 billion yuan, accounting for more than 40% of the market share. Among them, remifentanil hydrochloride for injection is as high as 90.28% of the market share, sitting firmly on the throne of "anesthesia first", its market position is rock-solid. Humanwell Healthcare will continue to uphold the philosophy of continuous innovation and excellence to further consolidate its leading position in the field of anesthetics. At the same time, the company will also accelerate the research and development process of new product pipelines, actively expand other therapeutic areas, and continuously improve its overall competitive strength with a diversified product portfolio and strong research and development strength. We firmly believe that with the joint efforts of all employees, Humanwell Healthcare will be able to create even more brilliant results and bring even greater returns to shareholders.

Drug Approval

26 Jun 2024

·www.prnewswire.com

Medasense Announces a Strategic Agreement With Global Medical Company, Nihon Kohden Corporation

RAMAT GAN, Israel, June 26, 2024 /PRNewswire/ -- Medasense, a global leader in pain monitoring solutions, is proud to announce a strategic partnership with Nihon Kohden for the exclusive distribution of its revolutionary pain monitoring device in Japan. This partnership is intended to transform pain management practices across Japanese healthcare facilities, offering a significant advancement in patient care. Nihon Kohden, renowned for its history of excellence in providing innovative high quality, reliable medical technology that improves the way healthcare is practiced, is partnering with Medasense to introduce its nociception monitor to the Japanese market. This cutting-edge device, with its state-of-the-art AI powered NOL - Nociception Level Index®, provides real-time, objective pain monitoring, enabling the personalization and optimization of pain treatment. It will be accessible to hospitals and clinics throughout Japan through Nihon Kohden's extensive distribution channels pending regulatory approval. Medasense's CEO & Founder, Galit Zuckerman, expressed enthusiasm about the collaboration: "We are honored to partner with Nihon Kohden, a company with a long history of excellence, that shares our vision of improving patient care through innovative solutions. Our mission is to help all patients suffer less from pain and the adverse effects of pain medication. Nihon Kohden's established clinical, technological leadership and expertise in the Japanese market make them the perfect partner to distribute our nociception monitor." NOL monitoring provides an AI powered, clinically validated index to objectively quantify the physiological response to pain (nociception) supporting clinicians in delivering personalized anesthesia tailored to patient requirements. With over 40 peer reviewed publications, clinical studies have demonstrated that NOL-guided analgesia resulted in intraoperative opioid sparing, and improved post operative pain scores and patient recovery.1,2 For more information about Medasense and Nihon Kohden, please visit and . About Medasense and NOL – Nociception Level Index® Technology Medasense is transforming pain management with its breakthrough technology that empowers clinicians to optimize and personalize pain control, significantly reducing the risk of pain or of overmedication. The company's flagship product, the PMD-200™, equipped with the NOL-Nociception Level Index®, leverages advanced artificial intelligence and a proprietary non-invasive sensor system. This unique platform provides objective monitoring and quantification of a patient's pain response, making it an essential tool in an operating room and critical care unit settings where patients cannot communicate their pain levels. The PMD-200 is the first and only monitor to be authorized by the FDA for pain measurement for anaesthesiology. It has been used in over 100,000 surgeries worldwide, and is commercially available in the US, Europe, Canada, Latin America and Israel. Watch Medasense's 1-minute video About Nihon Ko hden Founded in 1951, Nihon Kohden is a global leader of medical solutions with the goal to improve healthcare with advanced technology. For more than 70 years, Nihon Kohden has continued to provide a wide range of medical electronic equipment including EEG, EMG/EP measuring systems, electrocardiographs, bedside monitors, defibrillators, AEDs, ventilators, and hematology instruments. Nihon Kohden utilizes cutting-edge technology to support medical treatment in all clinical areas, integrating medical devices into the IT network to meet customers' requirements and offers a wide, comprehensive solution. For further information please contact: Rachel Weissbrod, VP Clinical & Market Development, Medasense +972-54-544-9115 [email protected] 1. Meijer, F., Honing, M., Roor, T., Toet, S., Calis, P., Olofsen, E., Martini, C., van Velzen, M., Aarts, L., Niesters, M., Boon, M., Dahan, A. (2020). Reduced postoperative pain using Nociception Level-guided fentanyl dosing during sevoflurane anaesthesia: a randomised controlled trial. British Journal of Anaesthesia, In Press. DOI: 2. Fleur S. Meijer, Chris H. Martini, Suzanne Broens, Martijn Boon, Marieke Niesters, Leon Aarts, Erik Olofsen, Monique van Velzen, Albert Dahan. Nociception-guided versus Standard Care during Remifentanil–Propofol Anesthesia: A Randomized Controlled Trial. Anesthesiology (2019); 130:745–755 Logo:

10 Jun 2024

·www.prnewswire.com

Indivior Announces Dosing of First Subject with INDV-2000 in a Phase 2 Study Assessing the Safety and Efficacy of INDV-2000 in Individuals with Opioid Use Disorder

Double-blind, placebo-controlled study aims to measure safety and efficacy of INDV-2000 over 3 months in participants with moderate to severe Opioid Use Disorder. INDV-2000 is an investigational non-opioid treatment that acts through the orexin pathway, shown to play a key role in the neurobiology of substance use disorder in animals. Recent animal studies have demonstrated that selective Orexin-1 receptor antagonism can reduce self-administration of opioids and synthetic opioids such as fentanyl and remifentanil. RICHMOND, Va., June 10, 2024 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced the dosing of the first subject with INDV-2000 in a Phase 2 double-blind, placebo controlled, randomized, dose-ranging study to assess the safety and efficacy of INDV-2000 over 3 months in treatment-seeking individuals with Opioid Use Disorder (OUD) (NCT06384157). The purpose of this proof-of-concept study is to measure safety and efficacy and to determine the dose-response relationship for INDV-2000 in participants with moderate to severe OUD who are treatment-naïve, have recently initiated or completed short-term medically supervised opioid withdrawal with transmucosal (TM) buprenorphine, and are interested in transitioning to a non-opioid treatment. This milestone is another step in Indivior's mission to develop new treatment options for patients with OUD and other substance use disorders. With the support of an NIH-HEAL grant (1R01DA043898-01A1) titled "Clinical Evaluation of INDV-2000 (C4X3256), a Non-Opioid, Highly Selective Orexin-1 Receptor Antagonist for the Treatment of Opioid Use Disorder" the study was initiated for the clinical development of INDV-2000, a potent and selective oral orexin-1 receptor (OX1R) antagonist, with demonstrated activity in rodent models of addiction and a safety profile suitable for therapeutic administration in clinical studies.1 More recently, animal studies also have shown that selective antagonism of the OX1R can reduce heroin intake and oxycodone self-administration2 and reduce the consumption of synthetic opioids including remifentanil3 and fentanyl.4 "INDV-2000 provides Indivior with a unique opportunity to further address unmet patient needs in the treatment of OUD with potentially the first non-opioid orexin-targeted therapy," said Christian Heidbreder, Chief Scientific Officer. "By providing a potential therapeutic option for patients who might benefit from a non-opioid alternative, INDV-2000 may broaden the spectrum of care for OUD treatment." The orexin-A and orexin-B neuropeptides are agonists of the orexin-1 receptor (OX1R) and orexin-2 receptor (OX2R), respectively. The OX1R and OX2R are thought to play differential physiological roles with the OX1R mainly involved in motivation and reward and the OX2R in the modulation of the sleep/wake cycle and energy homeostasis.3 The completion of clinical Phase 1 Single Ascending Dose (NCT04413552) and Multiple Ascending Dose (NCT04976855) studies happened after an end-of-Phase 1 meeting with the FDA on November 3, 2023, paving the way for the preparation and initiation of this clinical Phase 2 proof-of-concept (PoC) study. Opioid use disorder (OUD) involves disruption of brain circuits engaged in reward, decision-making, learning, and self-control. The magnitude of OUD worldwide highlights the need for novel molecular entities ultimately translating into new medications for the treatment of OUD. In the United States, among people aged 12 or older in 2022, 3.2% (or 8.9 million people) misused opioids in the past year.5 "As the opioid epidemic continues to escalate, it is important to develop more treatment options," said Dr. Heidbreder. "This milestone highlights Indivior's commitment to developing a wider range of therapeutics in both the opioid and non-opioid treatment category, ultimately providing more choices for the patient." About the Study The purpose of this Phase 2 study is to measure safety and efficacy and to determine the dose-response relationship for INDV-2000 in participants with moderate to severe Opioid Use Disorder (OUD) who are new to treatment, have recently initiated or completed short-term medically supervised opioid withdrawal with TM buprenorphine, and are interested in transitioning to a non-opioid treatment. On Day 1, trial participants will be randomized to the INDV-2000 or placebo group and receive the treatment in conjunction with TM buprenorphine until Day 7. From Day 8 onward, INDV-2000 or placebo will be administered as a standalone. The randomized treatment period starts when the participant receives randomized treatment (at Day 1) and ends at his/her last study visit after 3 months on INDV-2000 or placebo. Alternatively, the treatment period ends when participants initiate buprenorphine rescue therapy due to a relapse in illicit opioid use. About Indivior Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD), opioid overdose and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid use disorder treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and cooccurring disorders of SUD. Headquartered in the United States in Richmond, VA, Indivior employs more than 1,100 individuals globally and its portfolio of products is available in 37 countries worldwide. Visit to learn more. Connect with Indivior on LinkedIn by visiting . Important Cautionary Note Regarding Forward-Looking Statements This news release contains certain statements that are forward-looking. Forward-looking statements include, among other things, statements regarding potential new productor or therapies, express or implied statements about their safety and efficacy, and other statements containing the words "believe", "anticipate", "plan", "expect", "intend", "estimate", "forecast," "strategy," "target," "guidance," "outlook," "potential", "project", "priority," "may", "will", "should", "would", "could", "can", "outlook," "guidance", the negatives thereof, and variations thereon and similar expressions. By their nature, forward-looking statements involve risks and uncertainties as they relate to events or circumstances that may or may not occur in the future. Actual results may differ materially from those expressed or implied in such statements because they relate to future events. Various factors may cause differences between Indivior's expectations and actual results, including, among others, the risk that the clinical trial may fail to demonstrate the safety or efficacy of the treatment; that the FDA will require one or more Phase 3 trials before approving INDV-2000 for individuals with opioid use disorder; that the FDA may decline to approve INDV-2000 for individuals with opioid use disorder for many other reasons; and the material risks described in the most recent Indivior PLC Annual Report and in subsequent releases. Forward-looking statements speak only as of the date that they are made and should be regarded solely as our current plans, estimates and beliefs. Except as required by law, we do not undertake and specifically decline any obligation to update, republish or revise forward-looking statements to reflect future events or circumstances or to reflect the occurrences of unanticipated events. References Murray CM, Fox JC, Heidbreder C, Young M. A Novel, Non-Opioid, Selective Orexin-1 Receptor Antagonist for the Treatment of Substance Use Disorders. Neuroscience Applied, Volume 3, 2024, 104053. . Epub ahead of print. Smith, R.J., Aston-Jones, G., 2012. Orexin / hypocretin 1 receptor antagonist reduces heroin self-administration and cue-induced heroin seeking. Eur. J. Neurosci. 35, 798–804. Mohammadkhani, A., James, M.H., Pantazis, C.B., Aston-Jones, G., 2020. Persistent effects of the orexin-1 receptor antagonist SB-334867 on motivation for the fast-acting opioid remifentanil. Brain Res. 1731:146461. Fragale, J E., Pantazis, C.B., James, M.H., and Aston-Jones, G., 2019. The role of orexin-1 receptor signaling in demand for the opioid fentanyl. Neuropsychopharmacology. 44, 1690–1697. Substance Abuse and Mental Health Services Administration. (2022) Highlights for the 2022 National Survey on Drug Use and Health1. Retrieved from Highlights for the 2022 National Survey on Drug Use and Health (samhsa.gov) SOURCE Indivior PLC

Phase 2Phase 1

100 Deals associated with Remifentanil Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D01177	Remifentanil Hydrochloride	N01AH06	DB00899

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pain	CH	GSK Plc	28 Jan 1997
Anesthesia	US	Mylan Institutional LLC	12 Jul 1996

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hyperalgesia	Phase 3	DE	Air Liquide Santé (International) SA	01 Jan 2012
Pain	Phase 3	KR	GSK Plc	01 Apr 2008
Analgesia	Preclinical	DE	GSK Plc	01 Nov 2006
Sedation	Preclinical	DE	GSK Plc	01 Nov 2006
Analgesia	Discovery	DE	GSK Plc	01 Nov 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04734418 (Pubmed \| J Intensive Care) Manual	Not Applicable	-	179	Remifentanil	jrsqjbewrl(yoymxhfvgy) = kufpeyhrsk cevarodrlc (aktkfbfitg ) View more	Negative	18 Sep 2024
				Dexmedetomidine	jrsqjbewrl(yoymxhfvgy) = pofrskxtxz cevarodrlc (aktkfbfitg ) View more
NCT02631135 (CTgov)	Phase 4	-	40	Propofol+Rocuronium+Remifentanil (Group 1 (TIVA))	aleffoufzu(vqxgwknblz) = xxsbeyukpi nxgfgyyucd (yotprvrnvj, qvdfxupcgr - zjnglkydvv) View more	-	17 May 2024
				Dexmedetomidine+Propofol+Rocuronium+Remifentanil (Group 2 (TIVA+D))	aleffoufzu(vqxgwknblz) = yaxomedfwg nxgfgyyucd (yotprvrnvj, bolirsxwnv - afsgpigxhs) View more
NCT03207100 (Pubmed) Manual	Not Applicable	Cerebral Hemorrhage	338	remifentanil + dexmedetomidine	zrijowfjgt(kjvaoezwuc) = zmesugyhzs mxnfdzprrs (vdiuygntpp )	Positive	27 Mar 2024
				remifentanil	zrijowfjgt(kjvaoezwuc) = jedixtetiy mxnfdzprrs (vdiuygntpp )
NCT03643796 (CTgov)	Phase 4	Intervertebral Disc Disease	32	Remifentanil (Remifentanil Group)	gieldaorss(hfkuoouzai) = djfdpiaqfx blwpekjdfw (aqbdoarkgo, fpoqtfluhh - ijcitqfzty) View more	-	18 Sep 2023
				Dexmedetomidine+Ketamine (Ketamine and Dexmedetomidine Group)	gieldaorss(hfkuoouzai) = ahqfxkbbmh blwpekjdfw (aqbdoarkgo, hsxfbtwlfu - viytfludyu) View more
ChiCTR2100054565 (Pubmed)	Phase 4	-	-	Remifentanil	upgrpghdwr(zvfietgxhn) = which occurred in 3 patients nusfnlakik (awgbdysrbk )	-	28 Jun 2023
NCT02989597 (MAPS, CTgov)	Phase 4	Pain, Postoperative	10	Spinal Fusion Surgery+Sufentanil+Methadone Hydrochloride+Dexamethasone+ketamine+Remifentanil (Intra-operative Methadone Hydrochloride)	tenvwknhvj(ylkmxakffc) = pnpqynftgb jmfnevqevr (xaiusmeigq, ujnqaeelvr - aeldcasinz) View more	-	25 Apr 2023
				Spinal Fusion Surgery+Sufentanil+Dexamethasone+ketamine+Remifentanil (Control)	tenvwknhvj(ylkmxakffc) = rbicxphfyg jmfnevqevr (xaiusmeigq, xpcgsdabki - smailtbyyw) View more
NCT03283150 (CTgov)	Phase 4	Brain Diseases \| Sedation	20	Remifentanil (Remifentanil)	wjuwbrzqcg(dlwbuutrsr) = djsquuccpi szbkmurboz (bzsbeyneiq, tyxzivjmpy - lpjfjveatq) View more	-	27 Mar 2023
				Propofol (Propofol)	tfzdqrrxzo(twezjpabpm) = gdamaclsxb okurnyyrek (lkageqljbc, zvvhwcfxwe - ujedcsaupw) View more
NCT05217238 (Pubmed)	Not Applicable	Pain	-	Remifentanil (Group R1)	htkyrnncyq(ryjoylfyac) = vtbodmibdu cobbcdzfpx (zybplqmlhp, 1.186 - 1.351)	-	08 Mar 2023
				Remifentanil (Group R2)	htkyrnncyq(ryjoylfyac) = sqfxhxngzl cobbcdzfpx (zybplqmlhp, 1.065 - 1.324)
NCT03960801 (Pubmed)	Phase 3	-	1,150	Neuromuscular blockers	yzxdkbebin(dnkrzeecky) = vevnwpqzdu vkkkyrzhkw (wdoynlnltf )	-	03 Jan 2023
				Remifentanil	yzxdkbebin(dnkrzeecky) = jvctyfativ vkkkyrzhkw (wdoynlnltf )
NCT03996148 (CTgov)	Phase 4	Carotid Stenosis	21	Propofol+Desflurane+Remifentanil (Remifentanil, Propofol, and Desflurane)	xcrlcnqfkn(nzzjdpjtyq) = otwveuflyp khlsrbsagi (wyaycaztro, wawiughkxv - lzncguxvhm) View more	-	06 Apr 2022
				Dexmedetomidine+Desflurane+Remifentanil (Remifentanil, Dexmedetomidine, and Desflurane)	xcrlcnqfkn(nzzjdpjtyq) = buvtafzhrj khlsrbsagi (wyaycaztro, gyzcokxcdv - doizzydpah) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis